

**Krintafel (tafenoquine)**  
**Effective February 1, 2020**

<b>Plan</b>	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

### Overview

Tafenoquine in an 8-aminoquinolone antimalarial drug active against pre-erythrocytic (liver) forms (including hypnozoite [dormant state]) and erythrocytic (asexual) forms as well as gametocytes, of *Plasmodium* species, including *P. falciparum* and *P. vivax*. Activity against pre-erythrocytic liver stage prevents development of the erythrocytic forms of the parasite, which are responsible for relapses in *P. vivax* malaria.

Limitation of use: not indicated for the treatment of acute *P. vivax* malaria.

### Coverage Guidelines

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

1. The member is  $\geq 16$  years of age
2. The member has a diagnosis of *Plasmodium vivax* malaria and is receiving appropriate antimalarial therapy for acute *P. vivax* infection
3. The member has been tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency, and has a  $> 70\%$  of G6PD normal activity prior to initiating therapy with Krintafel

### Limitations

1. Authorizations will be approved for a maximum of 2 tablets (300 mg total) per request

## References

1. Krintafel (tafenoquine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2018.
2. Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med 2019; 380:215.
3. Rueangweerayut R, Bancone G, Harrell EJ, et al. Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers. Am J Trop Med Hyg 2017; 97:702.

## Review History

11/20/19 – Reviewed at P&T

11/18/2020- Reviewed at P&T.

